Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
How do you adjust enfortumab vedotin dosing due to side effects?
Do you adjust schedule or dose? Does the toxicity (e.g. rash vs neuropathy) matter?
Related Questions
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Is bilateral hearing loss requiring hearing aids an absolute or relative contraindication for neoadjuvant cisplatin in MIBC?
Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?
How would you manage metastatic small cell bladder cancer in a patient who is platinum ineligible?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
Is there a role for single agent immunotherapy in a patient with T2 muscle-invasive bladder cancer without lymph nodes or distant metastasis who declines chemotherapy and cystectomy?
Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?
In what situations would you recommend neoadjuvant chemotherapy prior to chemo/RT when pursuing bladder preservation in locally advanced bladder cancer?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?